19:50 , Jul 6, 2018 |  BC Extra  |  Preclinical News

New uses for marketed drugs in tough-to-treat indications

Two studies in Science Translational Medicine suggest three generics could be repurposed for difficult to treat indications. A paper from University of Edinburgh researchers showed that endothelial cell-targeted drugs simvastatin and perindopril could help treat patients...
15:16 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Cell culture and rat studies suggest nanoparticles loaded with cerivastatin could help treat pulmonary arterial hypertension (PAH) without the cytotoxicity of free cerivastatin. In a rat model of PAH, intratracheal administration of liposomes...
16:08 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Esperion's bempedoic acid combo meets in Phase II for hypercholesterolemia

Esperion Therapeutics Inc. (NASDAQ:ESPR) reported top-line data from the Phase II 1002-038 trial in 63 patients with hypercholesterolemia showing that the once-daily combination of 180 mg bempedoic acid (ETC-1002)/10 mg Zetia ezetimibe plus 20 mg...
00:16 , Aug 9, 2017 |  BC Extra  |  Clinical News

Esperion to raise funds after reporting bempedoic acid LDL-C data

Esperion Therapeutics Inc. (NASDAQ:ESPR) proposed to raise $150 million in a follow-on after market close on Tuesday following its announcement earlier in the day that oral bempedoic acid (ETC-1002)/Zetia ezetimibe plus Lipitor atorvastatin met the...
23:33 , Jul 13, 2017 |  BC Innovations  |  Strategy

Everyone counts in GWAS

The debate about the value of genome-wide association studies (GWAS) took a new twist with a Cell publication showing complex traits such as height and schizophrenia are controlled by broad, interconnected swaths of the genome...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Shionogi endocrine/metabolic news

The U.S. District Court for the District of Columbia denied a motion from AstraZeneca seeking a temporary restraining order to prevent FDA from approving generic versions of Crestor rosuvastatin. After the ruling, Mylan...
07:00 , Jul 20, 2016 |  BC Extra  |  Company News

AZ facing more generic Crestor competition

On Tuesday, a federal judge in the U.S. District Court for the District of Columbia denied a motion from AstraZeneca plc (LSE:AZN; NYSE:AZN) seeking a temporary restraining order to prevent FDA from approving generic versions...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Rosuvastatin regulatory update

FDA granted final approval to an ANDA from Allergan for a generic version of cholesterol drug Crestor rosuvastatin. The company launched the generic HMG-CoA reductase inhibitor in the U.S. It is approved to treat...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Zetia ezetimibe regulatory update

Merck said FDA issued a complete response letter for sNDAs that were seeking to add claims of cardiovascular benefit to the labels of Vytorin ezetimibe/simvastatin and Zetia ezetimibe. The pharma markets the drugs to...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Vytorin regulatory update

Merck said FDA issued a complete response letter for sNDAs that were seeking to add claims of cardiovascular benefit to the labels of Vytorin ezetimibe/simvastatin and Zetia ezetimibe. The pharma markets the drugs to...